CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome

Tuteja, Ashok K., Talley, Nicholas J., Stoddard, Gregory J., Verne, G. Nicholas · 2019 · Digestive Diseases and Sciences

Abstract

Background Irritable bowel syndrome (IBS) occurs in up to 33% of Gulf War (GW) Veterans. Alterations in gut microflora including small intestinal bacterial overgrowth (SIBO) during deployment may play a role in development of IBS. Rifaximin is a minimally absorbed antibiotic speculated to improve IBS symptoms, in part, by restoring normal gut microflora. The aim of this study was to compare rifaximin to placebo on IBS symptoms and quality of life (QOL) in GW Veterans with IBS without constipation. Methods A double-blind, placebo-controlled study was performed. One hundred and twenty-two GW Veterans with IBS (Rome III) from our database and referral to gastroenterology and internal medicine clinics were screened. After a 2-week run-in period, 50 patients were randomized (1:1) to receive either rifaximin 550 gm or placebo twice daily for 2 weeks in a double-blind study. Patients were advised not to change their diet or medications during the study. The symptoms assessed were: (1) stool frequency, (2) stool consistency (Bristol stool scale, 1-7, very hard to watery), (3) urgency (1 = yes/0 = no daily for 7 days), (4) severity of abdominal pain (0-4, none to severe), (5) severity of bloating (1-4, none to severe), and (6) global improvement scale (1-7, substantially worse to substantially improved). These were recorded for 7 consecutive days and then averaged across the 7 days, to generate a continuous variable. The symptom data were compared after 2 weeks of treatment. QOL was a…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10620-018-5344-5

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Gulf War and Health. Update of health effects of serving in the Gulf War. Institute of Medicine: National Academy of Sciences, National Academies Press; 2016.

Cited by

See all 42

Metadata

Authors
Tuteja, A. K., Talley, N. J., Stoddard, G. J., & Verne, G. N.
Affiliations
  • University of Utah (US)
  • University of Newcastle Australia (AU)
  • Tulane University (US)
Corresponding author
Tuteja, Ashok K.
Venue
Digestive Diseases and Sciences
Published
2018-10-28
Volume
64
Issue
3
Pages
838-845
ISSN
  • 0163-2116 (ISSN-L)
  • 1573-2568
OpenAlex
W2898093380
Cited by
42
References
33
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 8 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 3
FWCI
3.10
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Digestive Diseases and Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • NOVA (University of Newcastle Australia) (submittedVersion)
Funders
  • Department of Veterans Affairs (1I01CX001477-01)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK099052)
  • Department of Defense (W81XWH-10-1-0593, W81XWH-15-1-0636)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Keywords
irritable bowel syndrome, rifaximin, lactulose breath test, small intestinal bacterial overgrowth, Gulf War veterans, quality of life, IBS symptoms, gut microbiota, antibiotic therapy, bloating, abdominal pain, stool consistency, IBS-QOL, Rome III criteria, IBS subtypes
MeSH terms
Gastrointestinal Microbiome, Rifaximin, Adult, Aged, Anti-Bacterial Agents, Bacteria, Breath Tests, Defecation, Double-Blind Method, Female, Humans, Lactulose, Male, Middle Aged, Predictive Value of Tests, Quality of Life, Time Factors, Veterans, Treatment Outcome, Irritable Bowel Syndrome, Gulf War

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome. https://app.cochat.ai/papers/10.1007/s10620-018-5344-5
The paper
Tuteja, A. K., Talley, N. J., Stoddard, G. J., & Verne, G. N. (2019). Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-018-5344-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.